M&A in mitochondrial therapies: New opportunities in rare diseases, neurology and beyond

In this week’s Expert View, Dr Cheryl Barton examines how mitochondrial therapeutics are moving from the margins of rare disease into the mainstream of drug development. Investor appetite is returning, pipelines are broadening, and deal activity is picking up pace.

According to market research, the mitochondrial therapeutics market is valued at  $2.32 billion in 2025. It is projected to reach $ 5.4 billion by 2035, growing at a CAGR of 8.8%, primarily driven by advances in gene therapy, enzyme replacement therapies and pharmacological agents, including drugs that modulate oxidative phosphorylation and mitochondrial biogenesis (Figure 1).

Figure 1: Mitochondrial Therapeutics Market Revenues ($bn), 2022-2035